Price Break For Cervical Cancer Shots In Developing World
Cervical cancer takes its greatest toll in the countries whose economies and health systems are poorest.
Women in those places are less likely than those in rich countries to get regular Pap tests to detect the cancers when it can be treated effectively.
Of the 275,000 women who die of cervical cancer each year, more than 85 percent, or at least 234,000, are in low-income countries.
But a vaccine that can prevent cervical cancer could go a long way toward lowering the risk in those less developed countries. Problem is, the shots are pretty expensive.
In the U.S., vaccines against human papillomavirus the Centers for Disease Control and Prevention $100 or more per shot. Private buyers in the U.S. pay even more. Three doses are recommended.
Now, Merck and GlaxoSmithKline, makers of the HPV vaccines Gardasil and Cervarix, respectively, have agreed to lower the prices for their vaccines to less than $5 a shot.
Until now, the best price available to public sector buyers was $13, according to the , which brokered the deal.
(From Shots: Health News from NPR)